In a rebuke to two of the largest diabetes drug makers, the World Health Organization has decided not to include a pair of widely used insulins on its newest list of essential medicines, because the agency determined that the costs did not justify additional benefits.
The WHO acknowledged the treatments — Sanofi’s Lantus and Novo Nordisk’s Levemir — are effective in helping patients control their blood sugar, but expressed concern that prices for these so-called analog insulins, which are genetically altered, make them less desirable than human insulins.
Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
